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Over the past decade there have been significant 
changes in the approach to the management of 
chronic obstructive pulmonary disease (COPD). 
Previously, drugs were used that had originally been 
developed for asthma and were relatively nihilistic 
with regard to COPD management. Currently, the availability and 
use of drugs that have been developed primarily for the COPD 
patient have become mainstream treatment. There is now more 
optimism and empathy towards this rapidly growing group of 
patients.
According to 2004 World Health Organization (WHO) estimates, 
64 million people have COPD and 3 million have died of the 
condition. The WHO also predicts that COPD will become the 
third leading cause of death worldwide by 2030.[1] It suggests that 
there are four very useful components to a COPD management 
plan: (i) assess and monitor disease; (ii) reduce risk factors; (iii) manage 
stable COPD; and (iv) manage exacerbations.
Assess and monitor disease
The correct diagnosis of COPD and its severity is essential if the 
appropriate treatment is to be prescribed. If COPD is suspected 
after taking a history and performing a clinical examination, it 
should be confirmed with spirometry. A forced expiratory volume 
in 1 second/forced vital capacity (FEV1/FVC) of <0.7, with no or 
minimal reversibility after the administration of an inhaled short-
acting bronchodilator, is in keeping with the diagnosis. The new 
GOLD (Global Initiative for Chronic  Obstructive Lung Disease) 
guidelines[2] have added symptoms and risk for exacerbations into 
the classification, which allows for a more evidence-based approach 
when deciding on appropriate medications.
Reduce risk factors
It is essential to discuss modifying or removing risk factors for 
COPD in all patients who have been diagnosed with the condition, 
as ongoing exposure to a risk factor results in a more rapid decline of 
FEV1. This most frequently involves advice on smoking cessation or 
attempts to reduce biomass exposure. Smoking cessation programmes 
have significant benefit to patients who have decided to quit the habit.
Manage stable COPD
Bronchodilators
Except in patients with very mild disease and minimal symptoms, 
short-acting bronchodilators (SABAs) alone are no longer 
routinely recommended for COPD. SABAs and short-acting 
anticholinergic agents are used ‘as required rescue medications’ 
and not for maintenance therapy. The backbone of treatment 
for most COPD patients is long-acting β2-agonists (LABAs) 
and long-acting muscarinic antagonists (LAMAs). These agents 
have been shown to provide improvements in dyspnoea, health-
related quality of life (QoL), lung function, rescue medication 
use, exercise capacity and exacerbation risk.[3-7] The decision as 
to which agent to start with is often based on patient preference, 
available finances (LABAs are usually less expensive than LAMAs) 
and preferred delivery device. There are many drug choices and 
brands to choose from (Table 1).
Over the past 10 years evidence has been emerging with regard 
to bronchodilator maintenance therapy in COPD patients. Large 
randomised studies such as TORCH and UPLIFT, with long-term 
follow-up of 3 and 4 years, respectively, have become landmark 
studies and the evidence on which many guidelines are based.[8,9] 
Bronchodilators are effective in most patients with COPD and not 
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only in those with reversible disease on 
spirometry. An important benefit of LABAs 
and LAMAs is their effect on decreasing 
dynamic hyperinflation, which directly 
affects QoL. 
The TORCH study compared four groups, 
placebo v. salmeterol and fluticasone alone and 
the latter v. a salmeterol-fluticasone combi-
nation (SFC) over 3 years (6 112 patients).[8] The 
primary outcome was death from any cause 
for the comparison between the combination 
regimen and placebo. The study also 
assessed frequency of exacerbations, health 
status and lung function over the 3 years. 
The results showed that the all-cause 
mortality was 12.6% in the combination 
therapy group, 15.2% in the placebo group, 
13.5% in the salmeterol group, and 16.0% 
in the fluticasone group. The hazard ratio 
for death in the combination therapy group 
compared with the placebo group was 0.825 
(95% confidence interval (CI) 0.681 - 1.002; 
p=0.052), corresponding to a 17.5% reduction 
in the risk of death.[8] This did, however, not 
meet the predetermined level of statistical 
significance (p=0.052). Even though not a 
primary outcome, it is important to note 
that SFC, compared with placebo, decreased 
the annual rate of exacerbations from 1.13 
to 0.85 and improved health status and lung 
function (p<0.001 for all comparisons with 
placebo).[8] There was, however, an increase 
in the risk of pneumonia in the groups that 
received inhaled corticosteroids (ICS); this 
will be discussed in more detail below.
UPLIFT was a 4-year randomised, double-
blind trial, which compared either tiotropium 
(a LAMA) or placebo in patients with 
COPD.[9] Importantly, 75% of patients in 
both groups were already on LABAs and 
ICS; therefore, any benefit was over and 
above that of standard therapy. The primary 
endpoints were the rate of decline in the 
mean FEV1 before and after bronchodilator 
use, starting on day 30. Secondary endpoints 
included measures of FVC, changes in 
St George’s Respiratory Questionnaire 
(SGRQ) score, number and timing of acute 
exacerbations of COPD and mortality. The 
study did not find a significant difference 
between the groups in the rate of decline 
of FEV1. However, there was a significant 
improvement in the SGRQ in the tiotropium 
group compared with the placebo group 
at each time point throughout the 4 years 
(ranging from 2.3 U to 3.3 U; p<0.001).[9] At 
4 years, tiotropium was also associated with a 
reduction in the risk of exacerbations, related 
hospitalisations, and respiratory failure.[9] 
There was no benefit in its primary outcome; 
however, all its secondary outcomes showed 
improvement. If we consider the main 
complaints of COPD patients, this drug was 
shown to have a real-life benefit. 
LABAs can be used safely without ICS in 
COPD compared with asthma. When adding 
an ICS in COPD, it is necessary to decide if 
the benefit will be greater than the increased 
risk of pneumonia. ICS in combination with 
LABAs has been shown in some studies 
to improve lung function and QoL and 
reduce exacerbations.[8,10] The best evidence 
for these benefits, however, is in patients with 
≥2 exacerbations per year, especially in GOLD 
groups C and D. In patients without frequent 
exacerbations, these agents should not be 
initiated or should be gradually discontinued 
owing to the risk of pneumonia. There have 
been concerns about withdrawal of ICS in 
patients who have received the medication 
inappropriately or who are stable on LABA-
LAMA-ICS. However, the WISDOM study 
found that in patients with severe COPD, 
who were receiving tiotropium plus sal-
meterol, the risk of moderate or severe 
exacerbations was similar among those who 
gradually discontinued ICS and those who 
continued with the medication. The study 
did, however, note a slightly greater decrease 
in lung function during the final step of ICS 
withdrawal, but it is nevertheless considered 
safe to discontinue these agents if their use is 
not indicated.[11]
The review article in this edition of CME 
discusses the diagnosis and classification of 
the severity of COPD.[12] 
The majority of COPD patients, especially 
as the severity of the condition increases, 
are not usually managed with one agent 
only. Combination therapy, including 2 or 
even 3 agents, possibly in the same dispen-
sing device, has become the ultimate 
management choice. It allows for improved 
patient compliance and disease control. 
There is growing interest in LABA/LAMA 
combinations, and as these combinations are 
not yet available in a single dispenser in South 
Africa (SA), the agents can be used together. 
There are numerous studies (although 
no large randomised controlled studies) 
demonstrating that combinations improve 
lung function and decrease exacerbation 
rates more than either component alone.
There is a trend in lower-income 
countries for ICS to be used early in the 
management of COPD. This is certainly 
true in SA, primarily because of the cost and 
availability in clinics and hospitals. COPD 
patients are mostly managed as asthmatics 
with ICS and SABAs, as required. This 
is not in the best interests of the patient; 
LABAs and possibly LAMAs should be 
available at clinic level.
Oral medications
Theophylline is still widely used as an oral 
bronchodilator, mainly because of its low 
cost and easy accessibility. Theophylline has 
been shown to improve QoL, but its toxicity 
profile limits its acceptability as a first-line 
agent. The SA guidelines[13] recommend 
considering low-dose theophylline (as an 
anti-inflammatory agent and with measure-
ment of blood levels) as a treatment option, 
and the GOLD guidelines[2] suggest it as an 
alternative if no other bronchodilators are 
available.
Phosphodiesterase inhibitors, such as 
roflumilast, inhibit the airway inflammatory 
processes associated with COPD. They have 
Table 1. Inhaler therapy for COPD available in South Africa
Drug class Available drug Trade name
Short-acting bronchodilators 
(SABAs)
Fenoterol
Salbutamol
Berotec
Ventolin/Astavent/Venteze
Long-acting bronchodilators 
(LABAs)
Formoterol
Salmeterol
Foratec
Serevent
Ultra-long-acting 
bronchodilators
Indacaterol Ombrez
Short-acting anticholinergics Ipratropium Atrovent
Long-acting muscarinic agents 
(LAMAs)
Tiotropium Spiriva/Forvent
Inhaled corticosteroids (ICS) Beclometasone
Ciclesonide
Budesonide
Fluticasone
Beclate/Beceze
Alvesco
Budaflam/Pulmicort/Inflammide
Flixotide
Combinations Fluticasone/salmeterol
Budesonide/formoterol
Ipratropium/β2-agonists
Seretide/Sereflo/Foxair
Symbicord
Atrovent Beta/Combivent/Duolin
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been shown to be effective in Phase III clinical 
trials and have recently been registered for use 
in SA. In a pooled analysis of 2 large trials, a 
significant 17% reduction in the frequency of 
moderate or severe acute exacerbations (AEs) 
was demonstrated.[14] This drug is expensive, 
but has been shown to be cost-effective if 
used in suitable patients, although there are 
significant gastrointestinal side-effects.[15]
Long-term macrolide antibiotics are 
not currently recommended by the GOLD 
guidelines. However, they may be considered 
in patients with >2 exacerbations per year. 
The use of macrolides for the prevention of 
AEs is based on their immunomodulatory 
and anti-inflammatory effects, which have 
been long recognised in patients with 
cystic fibrosis and diffuse panbronchiolitis. 
Macrolides decrease sputum production, 
inhibit biofilm formation and reduce 
production of different virulence factors; 
recently, antiviral effects have also been 
reported.[16] There have been a number 
of small studies showing the benefits of 
long-term macrolides. A recent randomised 
controlled trial of 1 142 patients with a 
1-year follow-up period, using azithromycin 
250 mg daily, showed that the median time 
to first AE was 266 days (95% CI 227 - 313) 
in the azithromycin group and 174 days 
(95% CI 143 - 215) in the placebo group 
(p<0.001). The hazard ratio for having an AE 
per patient-year in the azithromycin group 
was 0.73 (95% CI 0.63 - 0.84; p<0.001). 
They also demonstrated improved QoL, 
but there was a small increase in the risk 
for hearing loss in the treatment arm.[17] 
The side-effects of macrolides need to be 
considered and monitored when initiating 
therapy, as the most serious side-effects 
include ototoxicity (hearing loss, tinnitus 
and vertigo), cardiac arrhythmias (especially 
prolonged QTc interval) and hepatotoxicity.
When deciding on which agent to use, the 
GOLD method of classifying patients into 
their respective ABCD group allows one 
to make a better evidence-based choice of 
agents (Fig. 1). 
Inhalation device
An often forgotten component of COPD 
treatment is the decision about the type of 
inhaler device. Inhaler technique, regardless 
of the device, should be checked regularly 
at every consultation and, if incorrect, 
re-taught repeatedly. It is important 
to match the patient’s ability with the 
correct device. Because of the lower 
cost, pressurised metered-dose inhalers 
(pMDIs) are most commonly prescribed, 
and if used correctly are good options. 
They are, however, most often incorrectly 
used. Dry powder inhalers (DPIs) are the 
inhalers of choice in patients with poor 
hand-lung co-ordination. DPIs are usually 
more expensive than pMDIs, but are very 
popular as patients find them easier to 
use. An equally important determinant of 
choosing a device is the patient’s ability 
to generate adequate inspiratory flow. In 
advanced COPD and in those having an 
exacerbation, the patient may not be able 
to generate sufficient inspiratory pressure 
to trigger the release of medication in 
DPIs. Similarly, pMDIs may not be inhaled 
sufficiently deeply and nebulisation may be 
necessary. In advanced COPD, inspiratory 
muscles can become weaker and be a 
mechanical disadvantage in the presence 
of severe hyperinflation. During follow-up, 
inhaler choice should be regularly evaluated 
and a change made if necessary.
Manage exacerbations
A vital part of COPD management is to 
try to decrease the risk of AEs. It has been 
shown that AEs have a negative impact 
on patient prognosis. Soler-Cataluna et al.[18] 
showed that patients with the greatest risk of 
mortality were those with ≥3 AEs (hazard 
ratio 4.13; 95% CI 1.80 - 9.41). AEs also 
result in an accelerated decline in lung 
function, poor QoL and increased health 
resource use. As discussed above, many 
of the current treatments, including ICS, 
LABAs and LAMAs, have been shown to 
decrease AEs.
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Fig. 1. Pharmacological management of COPD, based on the GOLD classification (adapted from the 
GOLD guideline (http://www.goldcopd.org[2])). (PDE4 = type 4 phosphodiesterase.)
